Media Coverage

FNN Logo

Media — Stockhead interview with Tim Boreham

By |2021-03-04T04:24:05+00:00March 4th, 2021|

Renowned biotech entrepreneur Paul Hopper on raising money, picking biotech winners and his latest ASX venture

Listen / read article

Media — Proactive Investors

By |2021-03-02T07:36:44+00:00March 2nd, 2021|

Chimeric’s new very experienced COO has bold vision to move CAR T cell therapy forward

Watch video

Media — AFR Magazine

By |2021-02-25T22:53:35+00:00February 25th, 2021|

Cancer-free after 12 years: Why you’re hearing the C-word more often

Read article

Media — Bioshares

By |2021-02-15T01:09:47+00:00February 15th, 2021|

Chimeric Makes Strong Listing on ASX

Read article

Media — Proactive Investors

By |2021-02-12T04:04:43+00:00February 12th, 2021|

Tony Locantro of Alto Capital adds Chimeric Therapeutics to his top stocks list

Watch video

Media — Eureka Report interview with Alan Kohler

By |2021-01-26T01:58:47+00:00January 26th, 2021|

Chimeric Therapeutics: Fighting tumours with scorpion toxin

Read Article

Media — Australian Financial Review

By |2021-01-18T05:52:57+00:00January 18th, 2021|

Cancer biotech Chimeric soars 50pc on debut

Read Article

Media — ausbiz

By |2021-02-12T04:15:36+00:00January 17th, 2021|

Chimeric Therapeutics Chairman Paul Hopper interview with ausbiz

Watch Video

Media — The Market Herald

By |2021-01-17T04:34:19+00:00January 17th, 2021|

Chimeric Therapeutics (ASX:CHM) receives overwhelming support for $35m IPO

Read Article

Media — Australian Financial Review

By |2021-01-06T04:25:00+00:00January 6th, 2021|

CAR-T cancer therapy company Chimeric Therapeutics is set for a cracking start to listed life

Read Article